“The Food and Drug Administration issued emergency use authorization Saturday to Johnson & Johnson to distribute its single-dose coronavirus vaccine. According to data reviewed by the agency, the jab from the pharmaceutical and consumer goods giant proved to be 66 percent effective at preventing COVID-19 infections in clinical trials against the virus, though less effective against the South African variant. It was also 85 percent effective at circumventing severe infection and offered ‘complete protection’ from hospitalization death from COVID-19. While the pharmaceutical company is expected to start out small – with 20 million doses shipped by the end of March, and 100 million by the end of June – the vaccine is seen as easier to use and store than the Pfizer and Moderna vaccines, which required two doses and had to be frozen” – Daily Beast.